LncRNAH19 acts as a ceRNA of let-7g to facilitate EndMT in hypoxic pulmonary hypertension via regulating TGF-β signalling pathway

Author:

Yu xin1,Huang Jiabing1,Liu Xu2,Li Juan1,Yu Miao2,Li Minghui2,Xie Yuliang2,Li Ye1,Qiu Junyu1,Xu Zhou1,Zhu Tiantian2,Zhang Weifang1

Affiliation:

1. the Second Affiliated Hospital of Nanchang University

2. Xinxiang Medical University

Abstract

Abstract

Background Hypoxic pulmonary hypertension (HPH) is a challenging lung arterial disorder with remarkably high incidence and mortality rates, and the efficiency of current HPH treatment strategies is unsatisfactory. Endothelial-to-mesenchymal transition (EndMT) in the pulmonary artery plays a crucial role in HPH. Previous studies have shown that lncRNA-H19 (H19) is involved in many cardiovascular diseases by regulating cell proliferation and differentiation but the role of H19 in EndMT in HPH has not been defined. Methods In this research, the expression of H19 was investigated in PAH human patients and rat models. Then, we established a hypoxia-induced HPH rat model to evaluate H19 function in HPH by Echocardiography and hemodynamic measurements. Moreover, luciferase reporter gene detection, and western blotting were used to explore the mechanism of H19. Results Here, we first found that the expression of H19 was significantly increased in the endodermis of pulmonary arteries and that H19 deficiency obviously ameliorated pulmonary vascular remodelling and right heart failure in HPH rats, and these effects were associated with inhibition of EndMT. Moreover, an analysis of luciferase activity indicated that microRNA-let-7g (let-7g) was a direct target of H19. H19 deficiency or let-7g overexpression can markedly downregulate the expression of TGFβR1, a novel target gene of let-7g. Furthermore, inhibition of TGFβR1 induced similar effects to H19 deficiency. Conclusions In summary, our findings demonstrate that the H19/let-7g/TGFβR1 axis is crucial in the pathogenesis of HPH by stimulating EndMT. Our study may provide new ideas for further research on HPH therapy in the near future.

Publisher

Research Square Platform LLC

Reference45 articles.

1. Guidelines for the Treatment of Pulmonary Arterial Hypertension;Vazquez ZGS;Lung,2020

2. Channelopathy Genes in Pulmonary Arterial Hypertension;Welch CL;Biomolecules,2022

3. Chronic Thromboembolic Pulmonary Hypertension: An Update;Ruaro B;Diagnostics (Basel),2022

4. Advances in treatment of chronic thromboembolic pulmonary hypertension;Tzoumas A;Thromb Res,2022

5. Pulmonary Hypertension: A Brief Guide for Clinicians;Mandras SA;Mayo Clin Proc,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3